Background: 5-aza-2'-deoxycytidine (5azadC, decitabine) is a DNA hypomethylating 27 agent used in the treatment of myelodysplastic syndromes. Due to cytotoxic side effects dose 28 optimization is essential. This study defines and quantifies the effects of 5azadC on 29 chromosomal stability and telomere length, at clinically relevant dosages. 30 Methods: Human WIL2-NS cells were maintained in complete medium containing 0, 0.2 31 or 1.0µM 5azadC for four days, and analysed daily for telomere length (flow cytometry), 32 chromosomal stability (cytokinesis-block micronucleus cytome (CBMN-cyt) assay), and 33 global methylation (%5me-C). 34 Results: DNA methylation decreased significantly in 1.0 µM 5azadC, relative to control 35 (p<0.0001). Exposure to 1.0µM 5azadC resulted in 170% increase in telomere length 36 (p<0.0001), in parallel with rapid increase in biomarkers of DNA damage; (micronuclei (MN, 37 6-fold increase), nucleoplasmic bridges (NPB, a 12-fold increase), and nuclear buds (NBud, a 38 13-fold increase) (all p<0.0001). Fused nuclei (FUS), indicative of mitotic dysfunction, 39 showed a 5-and 13-fold increase in the 0.2µM and 1.0µM conditions, respectively (p = 40 0.001) after 4 days. 41 Conclusions: These data show that (i) clinically relevant concentrations of 5azadC are 42 highly genotoxic; (ii) hypomethylation was associated with increased TL and DNA damage; 43 and (iii) longer TL was associated with chromosomal instability. These findings suggest that 44 lower doses of 5azdC may be effective as a hypomethylating agent, while potentially 45 reducing DNA damage and risk for secondary disease. 46 C Bull et al,
48
Introduction 49 DNA methylation is essential for gene transcription control, possibly evolving from the need 50 to silence genes of parasitic or viral origin (1). Dysregulation of the epigenome is associated 51 with neoplastic changes and tumorigenesis (1, 2) . Hypermethylation contributes to the 52 aetiology, and a worsening of clinical symptoms in myelodysplastic syndromes (MDS) and 53 acute myeloid leukemia (AML). A bone marrow stem cell transplant offers the greatest 54 chance of cure, but this is not a viable option for many patients, particularly the elderly. In 55 some cases hypomethylating drugs such as 5-azacytidine and decitabine (5-aza-2'-56 deoxycytidine (5azadC)), used alone or in combination with other chemotherapeutics, can 57 extend survival time and improve quality of life (3). These regimens are, however, highly 58 cytotoxic and can lead to severe (acute) side effects. DNA damage resulting from treatment 59 can also cause longer term effects such as impaired immune function and development of 60 secondary cancers (3, 4) . It is essential to optimize treatment protocols to maximise efficacy, 61 while minimizing genotoxic side effects, and secondary health impact. 62 63 5azadC is an analogue of the pyrimidine nucleoside cytidine, in which the carbon at position 64 5 is replaced with nitrogen. It has been used therapeutically for the treatment of all MDS 65 subtypes since FDA approval in 2004 (3-5) . 5azadC binds irreversibly (covalently) with 66 DNA methyltransferase 1 (DNMT1), resulting in (i) adduct formation within the DNA 67 sequence which potentially obstructs DNA synthesis, and (ii) inhibition of DNMT1 from 68 catalysing further methylation reactions. The hypomethylating effect becomes more 69 pronounced after several cell divisions, as numbers of free DNMT1 molecules are gradually 70 depleted (6). The net effect is to reduce/reverse the degree of DNA methylation, thus 71 reactivating aberrantly silenced genes, such as tumor suppressors (6) . A review of decitabine 72 dosage protocols for MDS patients showed a range from 15-500 mg/m 2 infused over 1-6 C Bull et al, submitted to PLoS One, Nov 2019 Page 4 73 hours, with some as long as 120 hours. Resulting plasma concentrations ranged from 0.12 -74 5.6 µM (4). In a cohort of patients taking oral decitabine (in combination with 75 tetrahydrouridine (THU)) a >75% reduction in DNMT1 in peripheral blood mononuclear 76 cells (PBMC) was recorded, in parallel with (LINE-1) CpG methylation reduction of 77 approximately 10% (5).
79
Previous studies to determine the degree of cytotoxicity and DNA damage caused by 5azadC 80 have measured the extent to which H2AX, a key 'first responder' in a DNA breakage damage 81 response, is phosphorylated to generate γH2AX (7). While informative, this method is 82 specific to DNA breaks and does not capture the different forms of chromosomal instability 83 induced by hypomethylation and DNA replication stress. The cytokinesis-block 84 micronucleus cytome (CBMN-cyt) assay is a comprehensive, robust diagnostic tool for 85 detecting and quantifying several chromosomal instability events such as micronuclei, 86 nucleoplasmic bridges and nuclear buds. The micronucleus (MN), has been internationally 87 validated as a risk marker for cancer risk and cardiovascular disease mortality (8). To our 88 knowledge the impact of 5azadC has not previously been studied using the CBMN cytome 89 assay. However a previous study showed that 5azadC can induce MN due to malsegregation 90 and loss of chromosomes 1, 9, 15, 16 and Y (9) . Furthermore, an additional measure was 91 examined in the present study, examining frequencies of the novel biomarker FUSED nuclei 92 (FUS). FUS are indicative of failed chromatid separation, or telomere end fusions, and are 93 known to be sensitive to changes in methylation status (10). The aim of the current study was to examine the hypothesis that exposure to 5azadC, within a 113 clinically relevant range, would cause an increase in both chromosomal instability, and 114 telomere length (TL). A key aim was to define and quantify the types of DNA damage 115 induced. To test this, human WIL2-NS cells were cultured in the presence of 0, 0.2 or 1.0 116 µM 5azadC for 4 days. Samples were analysed daily for growth (nuclear division index), The percentage of viable cells reduced in the 1.0 µM condition from 98% at day 0 to 40.6% 222 at day 4 (p trend < 0.0001) ( Fig 1A) . Cells with necrotic morphology increased in both the 223 0.2 and 1.0 µM 5azadC conditions, to approximately 50% cell death in the 1.0 µM cultures 224 by day 4 (p trend = 0.003) ( Fig 1B) . Consistent with these observations, nuclear division 225 index (NDI) reduced significantly in both 5azadC concentrations ( Fig 1C) . Page 11 235 5azadC causes telomere lengthening and global hypomethylation 236 Exposure to 5azadC caused significant, dose dependent, increase in TL (Fig 2A) . In the 1.0 237 µM cultures TL increased by 172% from 19.2 ± 0.4 (mean ± SEM) at day 0, to 33.1 ± 0.6 at 238 day 1, 156% longer than TL of cells maintained in 0 µM 5azadC for the same period (21.2 ± 239 0.5). At days 3 and 4, TL in cells cultured in 1.0 and 0.2 µM 5azadC were ~150% and 240~130% greater, respectively, than that of cells cultured over the same time period without 241 5azadC (Fig 2A). [5azadC] accounted for 25.3% of variance in TL (p < 0.0001), 32.7% was 242 due to time (p < 0.0001), with 30% attributable to the interaction of both factors (p < 0.0001).
243
Area under the curve for TL versus time of cells cultured in 1.0 µM was 111, 28% greater 244 than that of untreated cells (AUC 87), and 5% greater than TL of cells grown in 0.2 µM 245 5azadC (AUC 91). In untreated (control) cells, and those exposed to the 0.2 µM 5azadC, global DNA 254 methylation increased progressively with time, possibly due to supraphysiological 255 concentrations of folic acid and methionine in RPMI. In the 1.0 µM 5azadC cultures 256 methylation decreased resulting in significant differences in methylation status between 257 conditions, in a dose-and time-dependent manner. In fact, 24% of variance in %5-meC was Page 12 258 attributable to [5azadC] (p = 0.002), 18% was due to time (p = 0.04), with 25.3% of variance 259 in methylation being explained by the interaction of [5azadC] with time (p = 0.3, not 260 significant) ( Fig 2B) . cultures (0 µM 5azadC) reduced to 6.5 ± 1.5 at day 4 ( Fig 3A) . NBuds represent gene amplification, often arising due to breakage-fusion-bridge cycling. 297 The frequency per 1000 BN cells containing one or more NBud increased from zero at day 0, 298 to 13 ± 0 at day 4 in the 1.0 µM culture, and 9 ± 1 in the 0.2 µM condition ( Fig 3C) . When examining the total combined frequency of BN cells containing a damage biomarker 315 (ie. one or more MN and/or NPB and/or NBud and/or FUS morphology) ), 30% of variance 316 was attributable to [5azadC] (p < 0.0001), 44% was attributable to time (p < 0.0001), and 317 24% of the observed variance could be explained by the interaction of both factors (p < 318 0.0001), leaving only 2% of the variance unexplained ( Fig 3E) . 319 Page 15 322 Discussion 323 5azadC (decitabine), is used therapeutically to treat myelodysplastic conditions with dosage 324 protocols resulting in plasma concentrations in the range of 0.12 -5.6 µM (4). The 325 hypothesis for the current work, that exposure to 5azadC, within a clinically relevant range, 326 would cause an increase in both chromosomal instability, and telomere length (TL), was 327 supported by the data. Topoisomerase II and CENP-B), resulting in mitotic disruption (10, 32). As predicted,
